Abstract
The farnesoid X receptor (FXR) is a nuclear receptor expressed in tissues exposed to high concentrations of bile acids such as the liver, kidney and intestine and functions as a bile acid sensor. FXR regulates the expression of various transport proteins and biosynthetic enzymes crucial to the physiological maintenance of lipids, cholesterol and bile acid homeostasis. The concept of reverse endocrinology, whereby the receptor is identified first, followed by the identification of ligands and the sequential elucidation of the physiological role of the receptor has been widely used for a number of orphan nuclear receptors. The design of synthetic high affinity ligands acting via these receptors not only helps to decipher the function of the receptor, but also should lead to the development of novel and highly specific drugs. The bile acid receptor FXR is a perfect example where this strategy helped with understanding the role of this receptor in cholesterol and bile acid homeostasis. Regulation of FXR through small-molecule drugs represents a promising therapy for diseases resulting from lipid, cholesterol and bile acid abnormalities.
Keywords: farnesoid x receptor, bile acid receptor, nuclear receptor, bile acids, fxr ligands, small molecule drugs, hyperlipidemia, cholestasis
Mini-Reviews in Medicinal Chemistry
Title: FXR, A Therapeutic Target for Bile Acid and Lipid Disorders
Volume: 5 Issue: 8
Author(s): Stefan Westin, Richard A. Heyman and Richard Martin
Affiliation:
Keywords: farnesoid x receptor, bile acid receptor, nuclear receptor, bile acids, fxr ligands, small molecule drugs, hyperlipidemia, cholestasis
Abstract: The farnesoid X receptor (FXR) is a nuclear receptor expressed in tissues exposed to high concentrations of bile acids such as the liver, kidney and intestine and functions as a bile acid sensor. FXR regulates the expression of various transport proteins and biosynthetic enzymes crucial to the physiological maintenance of lipids, cholesterol and bile acid homeostasis. The concept of reverse endocrinology, whereby the receptor is identified first, followed by the identification of ligands and the sequential elucidation of the physiological role of the receptor has been widely used for a number of orphan nuclear receptors. The design of synthetic high affinity ligands acting via these receptors not only helps to decipher the function of the receptor, but also should lead to the development of novel and highly specific drugs. The bile acid receptor FXR is a perfect example where this strategy helped with understanding the role of this receptor in cholesterol and bile acid homeostasis. Regulation of FXR through small-molecule drugs represents a promising therapy for diseases resulting from lipid, cholesterol and bile acid abnormalities.
Export Options
About this article
Cite this article as:
Westin Stefan, Heyman A. Richard and Martin Richard, FXR, A Therapeutic Target for Bile Acid and Lipid Disorders, Mini-Reviews in Medicinal Chemistry 2005; 5 (8) . https://dx.doi.org/10.2174/1389557054553802
DOI https://dx.doi.org/10.2174/1389557054553802 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biological Abilities of Rice Bran-Derived Antioxidant Phytochemicals for Medical Therapy
Current Topics in Medicinal Chemistry Acute Coronary Syndromes as Auto-Inflammatory Disorders
Current Pharmaceutical Design Protocatechuic Acid and Human Disease Prevention: Biological Activities and Molecular Mechanisms
Current Medicinal Chemistry Plasma Level of D-dimer is an Independent Diagnostic Biomarker for Deep Venous Thrombosis in Patients with Ischemic Stroke
Current Neurovascular Research Therapeutic Use of Antioxidants in Sepsis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Type 2 Diabetes and Risk for Functional Decline and Disability in Older Persons
Current Diabetes Reviews Implications of Pharmacogenetics for Oral Anticoagulants Metabolism
Current Drug Metabolism High-Density Lipoprotein Quantity or Quality for Cardiovascular Prevention?
Current Pharmaceutical Design Knowing is Half the Battle: Targeting Virulence Factors of Group A Streptococcus for Vaccine and Therapeutics
Current Drug Targets Novel Drug Therapies for Fertility Preservation in Men Undergoing Chemotherapy: Clinical Relevance of Protector Agents
Current Medicinal Chemistry Asymmetric Dimethylarginine: a Key Player in the Pathophysiology of Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis in Rheumatoid Arthritis?
Current Pharmaceutical Design Multiplexed Fluorescence Imaging of Tumor Biomarkers in Gene Expression and Protein Levels for Personalized and Predictive Medicine
Current Molecular Medicine Fish Oils and Vascular Disease Prevention: An Update
Current Medicinal Chemistry Modulation of Intracellular Restriction Factors Contributes to Methamphetamine- Mediated Enhancement of Acquired Immune Deficiency Syndrome Virus Infection of Macrophages
Current HIV Research Preface [Hot Topic: Recent Progress in Cardiovascular Gene Therapy;Emerging to Real Drug? (Guest Editor: Ryuichi Morishita)]
Current Gene Therapy Effect of Flavonoids on Human Health: Old Subjects but New Challenges
Recent Patents on Biotechnology subject Index To Volume 3
Current Drug Targets Pharmacogenetics of the Metabolic Disturbances and Atherosclerosis Associated with Antiretroviral Therapy in HIV-Infected Patients
Current Pharmaceutical Design Antimicrobial Peptides in Oral Cancer
Current Pharmaceutical Design Screening of Novel Inhibitors Against Leishmania donovani Calcium ion Channel to Fight Leishmaniasis
Infectious Disorders - Drug Targets